CAJ | 학술논문

目的：建立白消安（BU）联合环磷酰胺（CY）化疗预处理的小鼠异基因造血干细胞移植（allo-HSCT）后急性移植物抗宿主病（aGVHD）的小鼠动物模型。方法：BALB/C受鼠以BUCY方案化疗预处理，根据化疗剂量分3组：1～4 d分别予BU 35、38、40 mg·kg-1·d-1，5～6 d予CY 100 mg·kg-1·d-1，第8天尾静脉回输C57BL/6供鼠骨髓细胞（2×107个）和脾细胞（2×107个），移植后定期观察记录受鼠一般情况等以判断aGVHD 的程度。结果：BU剂量为40 mg·kg-1·d-1受鼠组小鼠移植后体质量进行性下降，移植后6 d内全部死亡。BU剂量为35 mg·kg-1·d-1受鼠组观察到轻微aGVHD的临床症状，小鼠长期存活。BU剂量为38 mg·kg-1·d-1受鼠组观察到典型aGVHD临床症状及病理改变。结论：经BUCY（BU 38 mg·kg-1·d-1+CY 100 mg·kg-1·d-1）方案预处理后回输异基因骨髓细胞（2×107个）和脾细胞（2×107个）能成功构建aGVHD实验动物模型。
목적：건립백소안（BU）연합배린선알（CY）화료예처리적소서이기인조혈간세포이식（allo-HSCT）후급성이식물항숙주병（aGVHD）적소서동물모형。방법：BALB/C수서이BUCY방안화료예처리，근거화료제량분3조：1～4 d분별여BU 35、38、40 mg·kg-1·d-1，5～6 d여CY 100 mg·kg-1·d-1，제8천미정맥회수C57BL/6공서골수세포（2×107개）화비세포（2×107개），이식후정기관찰기록수서일반정황등이판단aGVHD 적정도。결과：BU제량위40 mg·kg-1·d-1수서조소서이식후체질량진행성하강，이식후6 d내전부사망。BU제량위35 mg·kg-1·d-1수서조관찰도경미aGVHD적림상증상，소서장기존활。BU제량위38 mg·kg-1·d-1수서조관찰도전형aGVHD림상증상급병리개변。결론：경BUCY（BU 38 mg·kg-1·d-1+CY 100 mg·kg-1·d-1）방안예처리후회수이기인골수세포（2×107개）화비세포（2×107개）능성공구건aGVHD실험동물모형。
Objective: To establish an acute graft-versus-host disease experimental animal model after al-logeneic hematopoietic were stem cell transplantation conditioned with busulfan (BU) and cyclophosphamide (CY).Methods: BALB/C Recipients were divided into three groups accarding to 3 different doses of BU (35, 38, 40 mg?kg-1?d-1) for 4 days, followed by CY (100 mg?kg-1?d-1) for 2 days. On the 8th day recipient mice received bone marrow cells (2×107) and splenocytes (2×107) from the C57BL/6 donors. All recipients were monitored daily after hematopoietic stem cell transplantation for clinical manifestations of aGVHD.Results: The recipients conditioned with BU of 40 mg?kg-1?d-1 exhibited progressive weight loss and all died within 6 days after reinfu-sion. The recipients received BU of 35 mg?kg-1?d-1 had no signiifcant clinical manifestations of aGVHD with long-term survival. The recipients conditioned with BU dose of 38 mg?kg-1?d-1 exhibited severe aGVHD typical clinical symptoms and pathology manifestation.Conclusion: Through a BUCY-based conditioning regimen (BU 3 mg?kg-1?d-1+CY 100 mg?kg-1?d-1) together with the reinfusion of bone marrow cells (2×107) and splenocytes (2×107), aGVHD experimental animal model can be established.